Dr. Christopher J. Sayed shares insights on the growing emphasis on personalized care for hidradenitis suppurativa.

Hidradenitis suppurativa treatment experiences vary widely among patients; a new study highlights the need for personalised care and shared decision-making.

Topline data were announced from pivotal phase 3 studies evaluating povorcitinib in adults with moderate to severe hidradenitis suppurativa.

Patients with hidradenitis suppurativa are at increased risk of developing several common inflammatory arthropathies in the years following diagnosis.

Study authors examined the relationship between the use of combined oral contraceptives and the onset of hidradenitis suppurativa.

A new drug application for povorcitinib is expected to be filed in late 2025 to early 2026 to treat adult patients with ...

A panelist discusses how clinicians should systematically adopt evidence-based hidradenitis suppurativa (HS) guidelines while maintaining flexibility to tailor treatments to individual patient needs, ...

Newly released data from the phase 3 STOP-HS clinical trial program reveal positive results in hidradenitis suppurativa from ...

Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients with Hidradenitis ...

A recent review highlights how the Mediterranean diet can reduce inflammation and improve outcomes for chronic skin ...

—The results of a new survey indicate that many patients with hidradenitis suppurativa (HS)—especially Blacks and Hispanics—say that the color of their skin may indeed play a role in how ...